Surprisingly, clinical trials of anti-IL-22 monoclonal antibodies (mAb), ILV-094 (NCT00563524) and ILV-095 (NCT01010542), are discontinued because of no efficacy in psoriasis patients with PASI ≥ 11 and PGA ≥ 3 in active phases (Table 1). This evidence concerns the gene IL22 and psoriasis.